BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to announce a major achievement for the company—VINIA, its flagship red grape cell-based supplement, has now surpassed $50 million in cumulative sales. Notably, the vast majority of these sales have occurred within just four years since the product’s U.S. launch in May 2021, highlighting its rapid market adoption and consumer demand. VINIA®, developed using BioHarvest’s proprietary Botanical Synthesis platform technology, has also reached another key milestone, surpassing 50,000 active U.S. subscribers on recurring subscription plans as of February 16, 2025. This growing base of loyal customers underscores the product’s effectiveness and strong brand resonance in the nutraceutical market. The supplement has garnered widespread consumer approval, with approximately 8,000 verified customer reviews in the U.S. and an impressive rating of 4.8 out of 5 stars. These positive testimonials reflect VINIA’s efficacy and position it as a leader in the functional health supplement category, with strong potential for continued growth both domestically and internationally. Building on this momentum, BioHarvest Sciences is investing in its future scalability. The company has announced plans to expand its production capacity by a factor of four with the construction of a new 100-ton-per-year production facility. This state-of-the-art facility, expected to be operational by late 2026, will enable BioHarvest to meet increasing demand and support its ambitious growth strategy. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech #Investing #StockMarket #Nasdaq #Polyphenols #Resveratrol #BloodFlow #HealthyLiving #PlantBased #SustainableInnovation